EBS
Price
$7.58
Change
-$0.05 (-0.66%)
Updated
Sep 5 closing price
Capitalization
404.4M
60 days until earnings call
HROW
Price
$36.99
Change
+$0.79 (+2.18%)
Updated
Sep 5 closing price
Capitalization
1.37B
72 days until earnings call
Interact to see
Advertisement

EBS vs HROW

Header iconEBS vs HROW Comparison
Open Charts EBS vs HROWBanner chart's image
Emergent Biosolutions
Price$7.58
Change-$0.05 (-0.66%)
Volume$830.96K
Capitalization404.4M
Harrow
Price$36.99
Change+$0.79 (+2.18%)
Volume$355.52K
Capitalization1.37B
EBS vs HROW Comparison Chart in %
Loading...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EBS vs. HROW commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Buy and HROW is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (EBS: $7.58 vs. HROW: $36.99)
Brand notoriety: EBS and HROW are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EBS: 69% vs. HROW: 66%
Market capitalization -- EBS: $404.4M vs. HROW: $1.37B
EBS [@Pharmaceuticals: Generic] is valued at $404.4M. HROW’s [@Pharmaceuticals: Generic] market capitalization is $1.37B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 1 FA rating(s) are green whileHROW’s FA Score has 1 green FA rating(s).

  • EBS’s FA Score: 1 green, 4 red.
  • HROW’s FA Score: 1 green, 4 red.
According to our system of comparison, HROW is a better buy in the long-term than EBS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 7 TA indicator(s) are bullish while HROW’s TA Score has 5 bullish TA indicator(s).

  • EBS’s TA Score: 7 bullish, 4 bearish.
  • HROW’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, EBS is a better buy in the short-term than HROW.

Price Growth

EBS (@Pharmaceuticals: Generic) experienced а -8.67% price change this week, while HROW (@Pharmaceuticals: Generic) price change was -5.15% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

EBS is expected to report earnings on Nov 05, 2025.

HROW is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HROW($1.37B) has a higher market cap than EBS($404M). HROW YTD gains are higher at: 10.253 vs. EBS (-20.711). EBS has higher annual earnings (EBITDA): 344M vs. HROW (32.1M). EBS has more cash in the bank: 267M vs. HROW (53M). HROW has less debt than EBS: HROW (231M) vs EBS (668M). EBS has higher revenues than HROW: EBS (812M) vs HROW (228M).
EBSHROWEBS / HROW
Capitalization404M1.37B30%
EBITDA344M32.1M1,072%
Gain YTD-20.71110.253-202%
P/E Ratio2.89N/A-
Revenue812M228M356%
Total Cash267M53M504%
Total Debt668M231M289%
FUNDAMENTALS RATINGS
EBS vs HROW: Fundamental Ratings
EBS
HROW
OUTLOOK RATING
1..100
6815
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
83
Overvalued
PROFIT vs RISK RATING
1..100
10049
SMR RATING
1..100
3296
PRICE GROWTH RATING
1..100
4243
P/E GROWTH RATING
1..100
6411
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EBS's Valuation (54) in the Biotechnology industry is in the same range as HROW (83) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to HROW’s over the last 12 months.

HROW's Profit vs Risk Rating (49) in the Pharmaceuticals Other industry is somewhat better than the same rating for EBS (100) in the Biotechnology industry. This means that HROW’s stock grew somewhat faster than EBS’s over the last 12 months.

EBS's SMR Rating (32) in the Biotechnology industry is somewhat better than the same rating for HROW (96) in the Pharmaceuticals Other industry. This means that EBS’s stock grew somewhat faster than HROW’s over the last 12 months.

EBS's Price Growth Rating (42) in the Biotechnology industry is in the same range as HROW (43) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to HROW’s over the last 12 months.

HROW's P/E Growth Rating (11) in the Pharmaceuticals Other industry is somewhat better than the same rating for EBS (64) in the Biotechnology industry. This means that HROW’s stock grew somewhat faster than EBS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSHROW
RSI
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
76%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 17 days ago
76%
Bullish Trend 9 days ago
84%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 3 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
88%
Aroon
ODDS (%)
Bullish Trend 1 day ago
88%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
STPCX12.830.06
+0.47%
Saratoga Technology & Comm C
PRMTX176.200.15
+0.09%
T. Rowe Price Comm & Tech Investor
WRAAX13.84N/A
N/A
Wilmington Global Alpha Equities A
FDEQX75.73N/A
N/A
Fidelity Disciplined Equity
HNIDX14.71N/A
N/A
Harbor Diversified Intl All Cp Retire

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with SIGA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then SIGA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
-0.66%
SIGA - EBS
43%
Loosely correlated
-0.82%
VTRS - EBS
42%
Loosely correlated
+1.65%
ELAN - EBS
39%
Loosely correlated
+5.50%
HKMPF - EBS
34%
Loosely correlated
N/A
PAHC - EBS
33%
Poorly correlated
+0.97%
More

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with OGI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then OGI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
+2.18%
OGI - HROW
34%
Loosely correlated
+2.48%
AQST - HROW
34%
Loosely correlated
+7.11%
TKNO - HROW
33%
Poorly correlated
+2.83%
AMRX - HROW
32%
Poorly correlated
+0.73%
EBS - HROW
30%
Poorly correlated
-0.66%
More